60703-46-0

Usage

Uses

Used in Pharmaceutical Industry:
Pyrimidine, 2,4,6-trichloro-5-methoxyis used as an intermediate in the synthesis of various pharmaceuticals for its ability to contribute to the development of new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical sector, Pyrimidine, 2,4,6-trichloro-5-methoxyis utilized as an intermediate in the production of agrochemicals, aiding in the development of compounds with pesticidal or herbicidal properties.
Used in Research and Development:
Pyrimidine, 2,4,6-trichloro-5-methoxyis employed as a building block in research and development for the creation of new compounds with potential biological activities, contributing to the discovery of novel therapeutic agents or chemical entities with specific applications.
Safety Precautions:
Due to the potentially hazardous nature of Pyrimidine, 2,4,6-trichloro-5-methoxy-, it is crucial to handle and store Pyrimidine, 2,4,6-trichloro-5-methoxy- with proper safety measures to prevent any adverse effects on health or the environment.

InChI:InChI=1/C5H3Cl3N2O/c1-11-2-3(6)9-5(8)10-4(2)7/h1H3

Upstream product

• 60703-43-7 6-hydroxy-5-methoxypyrimidine-2,4(1H,3H)-dione 
• 1382980-32-6 C₅H₅N₂O₄^(1-)*Na⁽¹⁺⁾ 
• 71720-62-2 6-hydroxy-5-methoxy-1H-pyrimidine-2,4-dione,sodium salt 

Relevant academic research and scientific papers

HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF

The present disclosure relates to inhibitors of one or more isoforms of RAS, such as inhibitors of one or more of KRAS, HRAS and NRAS, or mutants thereof, such as G12D, G12V, G13D or G12C mutants thereof. Therapeutic methods of treating conditions and dis

Synthesis method of 2,4,6,-trichloro-5-methoxypyrimidine

The invention discloses a synthesis method of 2,4,6,-trichloro-5-methoxypyrimidine, the synthesis method comprises the following steps of: 1, mixing 2,4,6-trihydroxy-5-methoxypyrimidine, phosphorus oxychloride and an organic base according to a weight ratio of 1: 5-10: 0.33-0.7, and performing chlorination reaction at 25-100 DEG C for 2-5 hours; and 2, after the reaction is completed, cooling a mixture, concentrating the mixture under a reduced pressure to remove excess phosphorus oxychloride, quenching with water, extracting with an organic solvent, drying, and concentrating to obtain a product. The method not only improves the yield, shortens the time, is simple to operate, simplifies the post-treatment process, saves the cost, and is suitable for popularization.

DIOXINO-AND OXAZIN-[2,3-D]PYRIMIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE

Dioxino-and oxazin-[2,3-d]pyrimidine PI3K inhibitor compounds of Formula I with anti-cancer activity, anti-in-flammatory activity, or immunoregulatory properties, and more specifically with PI3 kinase modulating or inhibitory activity are de-scribed. Methods are described for using the tricyclic PI3K inhibitor compounds of Formula I for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, organisms, or associated pathological conditions.

TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE

Tricyclic PI3k inhibitor compounds of Formula I with anti-cancer activity, anti- inflammatory activity, or immunoregulatory properties, and more specifically with PI3 kinase modulating or inhibitory activity are described. Methods are described for using the tricyclic PI3K inhibitor compounds of Formula I for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, organisms, or associated pathological conditions. Formula I compounds include stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof. The dashed lines indicate an optional double bond, and at least one dashed line is a double bond. The substituents are as described.

NOVEL PYRIMIDINE COMPOUNDS AS MTOR AND P13K INHIBITORS

The present invention relates to pyrimidine compounds of formula (I): which are useful in treating mTOR kinase- or PI3K kinase-related diseases.

Pyrimidines

Compounds having the formula SPC1 Process for the preparation of such compounds which comprises reacting a pound having the formula: SPC2 Medicaments containing a compound of formula (I) or a salt thereof with a pharmaceutically acceptable acid; compounds